Stephen J. Freedland, MD

Stephen J. Freedland, MD, Warschaw Robertson Law Families Chair in Prostate Cancer, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, and professor of surgery, Cedars-Sinai Medical Center, discusses real-world data for enzalutamide (Xtandi) as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.

Relatively similar results were observed in the real-world data versus the PREVAIL study, which evaluated chemotherapy-naive patients who received enzalutamide. Freedland says the median prostate-specific antigen (PSA) decline was about 58%, and about 14% of patients had undetectable PSA levels.

A subset of patients did not respond to the treatment at all, and their PSA kept increasing, Freedland says. However, we know there can be inherent resistance to hormonal therapy. The median time to progression in this subset of patients was 18.5 months, Freedland also notes the reduction in PSA levels were a little lower perhaps because of drug compliance issues or investigators did not check PSA levels frequently enough to detect the best PSA decline. Time to PSA rise was a little longer, Freedland concludes.

Overall, these data are relatively similar to what has been observed in other trials. This gives researchers hope that patients can receive these drugs and experience similar benefits to what has been seen in clinical trials.

<< View more resources and information regarding prostate cancer

Videos

Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.

Real-World PSA Response Data Similar to Clinical Trials in Prostate Cancer

Stephen J. Freedland, MD, Warschaw Robertson Law Families Chair in Prostate Cancer director, Center for Integrated Research in Cancer and Lifestyle, co-directed, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, and professor of Surgery, at Cedar Sinai Medical Center, provided background on an analysis pf real-world patients with metastatic castration-resistant prostate cancer (mCRPC), which he presented at the 2020 Genitourinary Cancers Symposium (GU 2020).

Multiple phase III studies have shown that enzalutamide is a novel therapy for mCRPC. One of the questions that have come out of these clinical trials is, how does the efficacy translate in real-world patients. To answer this question, Freeland et al conducted a real-world analysis of prostate-specific antigen (PSA) outcomes among patients with mCRPC treated with enzalutamide.

For the analysis, the investigator reviewed data from nearly 1,000 male patients, using a medical record system that is used by about 30% of urologists in the United States. The patients who were included in the analysis had been treated before the approval of enzalutamide in mCRPC.

The results were similar to what was observed in the phase II PREVAIL trial (NCT01212991), says Freedland, with the median PSA being 58% and about 14% of patients reaching an undetectable PSA level.

<< View more from the 2020 Genitourinary Cancers Symposium

Stephen J. Freedland, MD, discussed&nbsp;an analysis real-world patients with metastatic castration-resistant prostate cancer, which he presented at the 2020 Genitourinary Cancers Symposium.

Real-World Responses to Enzalutamide Match Clinical Trial Responses in mCRPC

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index and prostate cancer risk.

The dietary patterns of men with cancer were compared to the patterns of healthy men without cancer.

Researchers hypothesized that more carbohydrates would lead to higher cancer risk, though the opposite was observed.

Evidence was also seen that carbohydrates with a higher gylcemic index increased risk of prostate cancer

Stephen J. Freedland, MD | Authors

Articles

Real-World PSA Response Data Similar to Clinical Trials in Prostate Cancer

Real-World Responses to Enzalutamide Match Clinical Trial Responses in mCRPC

Carbohydrate Intake, Glycemic Index, and Prostate Cancer Risk